Currently, most patients requiring blood dialysis for renal failure use arteriovenous fistulae or artificial vessels for vascular access.
However, previous treatment with autologous vessels has limitations on the collection of vessels, and previous artificial vessels have been considered problematic because of the frequent problems of infections and stenosis since they are made of artificial materials.
Thus, a number of patients receiving dialysis who reached the limitation in autologous vascular transplantation are keenly awaiting development of novel blood access different from autologous and artificial vascular transplantation.
Cyfuse has successfully developed a steric vascular structure consisting of cells only with its unique three-dimensional cell layering technology without using a scaffold.
The previous research and development confirmed that this vascular structure created only from cells, such as fibroblasts, is strong enough to bear blood pressure and maintain a long-term aperture.
From now on, Cyfuse intends to make further progress in the development of this cellular vessel to achieve a new approach where a vascular structure resistant to infection with high elasticity is implanted as independent tissue so as to provide novel treatment for patients, including diabetics with angiopathy receiving dialysis.
In addition to deployment of more difficult treatments, such as revascularization for severe ischemia in the lower extremities and coronary bypass, as well as expansion into the cerebrovascular field and pediatric vascular field, deployment into fields other than vascular fields is keenly awaited as well, such as the gastrointestinal and urinary organs from the progression of functional restoration technology using a tubular cellular structure created by cells only.
Patients in need of small-caliber cellular vessels